FinTrust Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

FinTrust Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-14	Closed	-$1.15K	–	1385
2024 Q2	$1.15K	Buy	+14	New	+$1.17K	﹤0.01%	1245
2022 Q2	–	Sell	-50	Closed	-$4K	–	1218
2022 Q1	$4K	Hold	50	–	–	﹤0.01%	1086
2021 Q4	$4K	Buy	+50	New	+$4.13K	﹤0.01%	1038
2021 Q2	–	Sell	-100	Closed	-$8K	–	1169
2021 Q1	$8K	Buy	+100	New	+$8.17K	﹤0.01%	939
2019 Q2	–	Sell	-14	Closed	-$1K	–	1070
2019 Q1	$1K	Hold	14	–	–	﹤0.01%	1172
2018 Q4	$1K	Buy	+14	New	+$1.33K	﹤0.01%	1184

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

FinTrust Capital Advisors's BMRN Position: Q3 2024 in Review

FinTrust Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 14 shares — an estimated $1.15K sold.

FinTrust Capital Advisors first reported a position in BMRN in Q4 2018 and held it in 6 quarters. The position peaked at $8K in Q1 2021. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

FinTrust Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
FinTrust Capital Advisors sold 14 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $1.15K.
FinTrust Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 6 quarters.
FinTrust Capital Advisors's BioMarin Pharmaceuticals position peaked at $8K in Q1 2021.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.